The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus

Journal of Endocrinology

Volumn 157, Issue 1, 1998, Pages 169-175

  Dryden, S ^a   Pickavance, L ^a   Tidd, D ^a   Williams, G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN THIRD VENTRICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG PENETRATION; FOOD INTAKE; GENE EXPRESSION REGULATION; HYPOTHALAMUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NEUROSECRETORY CELL; NONHUMAN; OSMOREGULATION; PRIORITY JOURNAL; RAT; THALAMUS MIDLINE NUCLEUS; TISSUE SECTION;

ANALYSIS OF VARIANCE; ANIMALS; CEREBRAL VENTRICLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EATING; GENE EXPRESSION REGULATION; HYPOTHALAMUS; INFUSION PUMPS, IMPLANTABLE; MALE; MICROSCOPY, FLUORESCENCE; NEUROPEPTIDE Y; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, WISTAR; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 0031978704     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1570169     Document Type: Article

References (30)

1. Akabayashi A, Wahlestedt C, Alexander JT & Leibowitz SF 1994 Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Molecular Brain Research 21 55-61.
2. Beck B, Jhanwar-Uniyal M, Burlet A, Chapleur-Chareau M, Leibowitz SF & Burlet C 1991 Rapid and localized alterations of neuropeptide Y in discrete hypothalamic nuclei with feeding status. Brain Research 528 245-249.
3. Bennett MR 1995 The use of antisense oligonucleotides as therapeutic agents: a review. Journal of Drug Development and Clinical Practice 7 225-235.
4. Billington CJ, Briggs JE, Grace M & Levine AS 1991 Effects of intracerebro-ventricular injections of neuropeptide Y on energy metabolism. American Journal of Physiology 260 R321-R327.
5. Boado RJ, Kang Y-S, Wu D & Pardridge WM 1995 Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond. Drug Metabolism and Disposition 23 1297-1300.
6. Brady LS, Smith MA, Gold PW & Herkenham M 1990 Altered expression of hypothalamic neuropeptide Y mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 52 441-147.
7. Chronwall BM, Dimaggio DA, Massari VJ, Pickel VM, Ruggiero DA & O'Donohue TL 1985 The anatomy of neuropeptide Y-containing neurons in the rat brain. Neuroscience 15 1159-1181.
8. Dryden S & Williams G 1996 The role of hypothalamic peptides in the control of energy balance and body weight. Current Opinion in Endocrinology and Diabetes 3 51-58.
9. Dryden S, Frankish HM, Wang Q & Williams G 1994 Neuropeptide Y and energy balance: one way ahead for the treatment of obesity? European Journal of Clinical Investigation 24 293-308.
10. Dryden S, Frankish HM, Wang Q, Pickavance L & Williams G 1996 The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 72 557-566.
11. Erickson JC, Clegg KE & Palmiter RD 1996 Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381 415-418.
12. Frankish HM, Dryden S, Hopkins D, Wang Q & Williams G 1995 Neuropeptide Y, the hypothalamus and diabetes: insights into the control of metabolism. Peptides 16 757-771.
13. Gao W-Y, Han F-S, Storm C, Egan W & Cheng Y-C 1992 Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNase H: implications for antisense technology. Molecular Pharmacology 41 223-229.
14. Gerald C, Walker MW, Criscione L, Gustafason EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitbread S, Hofbauer KG, Taber RI, Branchek TA & Weinshank RL 1996 A receptor subtype involved in neuropeptide Y-induced food intake. Nature 382 168-171.
15. Giles RV & Tidd D 1992 Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acid Research 20 763-770.
16. Heilig M 1995 Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regulatory Peptides 59 201-205.
17. Hulsey MG, Pless CM, White BD & Martin RJ 1995 ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regulatory Peptides 59 207-214.
18. Kalra SP, Dube MG, Sahu A, Phelps C & Kalra PS 1991 Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proceedings of the National Academy of Sciences 38 10931-10935.
19. Landgraf R 1996 Antisense targetting in behavioural neuroendocrinology. Journal of Endocrinology 151 333-340.
20. Morris BJ 1989 Neuronal localisation of neuropeptide Y gene expression in rat brain. Journal of Comparative Neurology 290 358-368.
21. Ogawa S, Brown HE, Okano HJ & Pfaff DW 1995 Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regulatory Peptides 59 143-149.
22. Paxinos G & Watson C 1986 The Rat Brain in Stereotaxic Coordinates, edn 2. Sydney: Academic Press.
23. Phillips MI & Gyurko R 1995 In vivo applications of antisense oligonucleotides for peptide research. Regulatory Peptides 59 131-141.
24. Spiller DG & Tidd DM 1992 The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anti Cancer Drug Design 7 115-129.
25. Stanley BG, Kyrkouli SE, Lampert S & Leibowitz SF 1986 Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7 1189-1192.
26. Szklarczyk A & Kaczmarek L 1995 Antisense oligodeoxynucleotides: stability and distribution after intracerebral injection into rat brain. Jounal of Neuroscience Methods 60 181-187.
27. Wahlestedt C, Pich EM, Koob GF, Yee F & Heilig M 1993 Modulation of anxiety and neuropeptide Y-Y1 rceptors by antisense oligodeoxynucleotides. Science 259 528-531.
28. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Waldbridge S, Alger JR & Neckers LM 1993 Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proceedings of the National Academy of Sciences 90 4665-4669.
29. Xu B, Sahu A, Kalra PS, Crowley WR & Kalra SP 1996 Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger ribonucleic acid antisense oligodeoxynucleotides. Endocrinology 137 78-84.
30. Yaida Y & Nowak TS Jr 1995 Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Regulatory Peptides 59 193-199.